M&A Deal Summary

Endo International Acquires BioSpecifics Technologies

On October 19, 2020, Endo International acquired life science company BioSpecifics Technologies for 540M USD

Acquisition Highlights
  • This is Endo International’s 10th transaction in the Life Science sector.
  • This is Endo International’s 7th largest (disclosed) transaction.
  • This is Endo International’s 13th transaction in the United States.
  • This is Endo International’s 1st transaction in Delaware.

M&A Deal Summary
Date 2020-10-19
Target BioSpecifics Technologies
Sector Life Science
Buyer(s) Endo International
Deal Type Add-on Acquisition
Deal Value 540M USD

Target

BioSpecifics Technologies

Wilmington, Delaware, United States
BioSpecifics Technologies Corp. is a commercial-stage biopharmaceutical company that discovers and develops a proprietary form of injectable collagenase (CCH), which is currently marketed by Endo, as XIAFLEX in North America for the treatment of Dupuytren's contracture and Peyronie's disease. Endo announced that it received FDA approval of CCH for the treatment of moderate to severe cellulite in the buttocks of adult women; Qwo is expected to be available commercially in the U.S. starting in the first half of 2021. The CCH research and development pipeline includes several additional potential indications including adhesive capsulitis and plantar fibromatosis.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Endo International

Dublin, Ireland
Category Company
Founded 1920
Sector Medical Products
Employees3,103
Revenue 2.9B USD (2020)
DESCRIPTION

Endo International is a pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Endo International was incorporatted in 1920 and is based in Dublin, Ireland.

DEAL STATS #
Overall 15 of 16
Sector (Life Science) 10 of 11
Type (Add-on Acquisition) 15 of 15
State (Delaware) 1 of 1
Country (United States) 13 of 14
Year (2020) 1 of 1
Size (of disclosed) 7 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-05 SOMAR

Benito Juarez , Mexico

SOMAR is a pharmaceutical company focused on the development, manufacture, and marketing of high-quality generic and branded generic products in Mexico. SOMAR focuses on a number of key primary care market segments including dermatology medications. SOMAR is based in Benito Juarez, Mexico.

Sell $124M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-02 Nevakar Injectables - Six Development-Stage Product

Bridgewater, New Jersey, United States

Nevakar Injectables' Six Development-Stage Product Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration.

Buy $35M
Mergr

Product

Company

Legal